Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York
Rhea-AI Summary
Abeona Therapeutics (Nasdaq: ABEO) activated NewYork-Presbyterian/Columbia University Irving Medical Center as a new Qualified Treatment Center for ZEVASKYN (prademagene zamikeracel) on April 2, 2026. This marks the company's fifth QTC and expands patient access across the New York metropolitan area and the Northeast.
The announcement highlights collaboration with Columbia dermatology leadership and notes Abeona Assist offers insurance, financial, travel, and logistical support for eligible patients seeking ZEVASKYN.
Positive
- Fifth QTC activated, expanding treatment capacity for ZEVASKYN
- Geographic expansion into New York metro area and broader Northeast
- Partnership with Columbia/NewYork-Presbyterian, adding clinical expertise
- Abeona Assist patient support for insurance, financial, travel, and logistics
Negative
- None.
News Market Reaction – ABEO
In the Apr 2 session, ABEO gained 5.24%, reflecting a notable positive market reaction. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 17 | Full-year results | Positive | -3.8% | Reported 2025 results, profitability aided by PRV sale and cash strength. |
| Mar 09 | Launch update | Positive | +6.4% | Highlighted growing ZEVASKYN launch momentum and broad payer coverage. |
| Mar 03 | Earnings call date | Neutral | -2.4% | Announced timing for Q4 and full‑year 2025 results and conference talk. |
| Feb 09 | Inducement grants | Neutral | +0.0% | Disclosed Nasdaq Rule 5635(c)(4) inducement awards to new employees. |
| Dec 31 | Inducement grants | Neutral | +1.7% | Approved additional restricted stock inducement awards for recent hires. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows positive reactions to ZEVASKYN commercial updates but a negative move on full‑year earnings and bylaw/governance activity.
Over the past several months, Abeona reported its transition to a commercial‑stage gene therapy company, including FDA approval and launch of ZEVASKYN, full‑year 2025 financial results, and multiple business updates on manufacturing and reimbursement progress. Other filings covered insider sales, ownership changes via Schedules 13G/13G/A, and amended bylaws that raised quorum requirements and strengthened shareholder proposal procedures. Today’s addition of a New York Qualified Treatment Center extends the commercialization narrative and access footprint for ZEVASKYN.
Key Terms
qualified treatment center medical
gene-modified cellular sheets medical
gene therapy medical
precision medicine medical
recessive dystrophic epidermolysis bullosa medical
epidermolysis bullosa medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CLEVELAND, April 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of NewYork-Presbyterian/Columbia University Irving Medical Center in New York, NY as the newest Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets.
“Activation of NewYork-Presbyterian/Columbia University Irving Medical Center as our fifth QTC significantly expands patient access to ZEVASKYN in the New York metropolitan area and across the Northeast,” said Dr. Madhav Vasanthavada, Chief Commercial Officer of Abeona. “Partnering with an institution recognized globally for its leadership in genetic medicines and long history in managing blistering skin disorders means that our patients will be supported by world-class clinical expertise throughout their treatment journey.”
Aimee Payne, MD, PhD, the Herbert and Florence Irving Professor and Chair of Dermatology at Columbia University Vagelos College of Physicians and Surgeons and Dermatologist-in-Chief at NewYork-Presbyterian, said, “Integrating this gene therapy underscores NewYork-Presbyterian and Columbia’s leadership in precision medicine and our deep commitment to the epidermolysis bullosa community. Our multidisciplinary model is designed to support these patients through a lifetime of care—including the critical transition from pediatric to adult medicine. For families navigating the daily burden of recessive dystrophic epidermolysis bullosa, this is more than a new option for healing skin—it is a vital step toward restoring their confidence, mobility, and hope.”
For more information on how to access ZEVASKYN and learn about patient support services offered through Abeona Assist®, Abeona’s comprehensive patient support program, visit www.abeonaassist.com, call 1-855-ABEONA-1 (1-855-223-6621) or email MyNavigator@AbeonaAssist.com. Abeona Assist offers personalized support, including helping eligible patients understand their insurance benefits and financial assistance options, and providing travel and logistical assistance.
About recessive dystrophic epidermolysis bullosa
Recessive dystrophic epidermolysis bullosa (RDEB), a rare blistering disorder without a cure, is characterized by severe skin wounds that cause pain and can lead to systemic complications impacting the length and quality of life. People with RDEB have a defect in both copies of the COL7A1 gene, leaving them unable to produce functioning type VII collagen, which is necessary to anchor the dermal and epidermal layers of the skin.
About ZEVASKYN® (prademagene zamikeracel) gene-modified cellular sheets
ZEVASKYN is the first and only autologous cell sheet-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). RDEB is a severe skin disease caused by a defect in both copies of the COL7A1 gene resulting in the inability to produce functional type VII collagen. Without functional type VII collagen and anchoring fibrils, the skin is fragile and blisters easily, leading to wounds that continually open and close, or fail to heal altogether. Patients often have large open wounds that can lead to serious life-threatening complications. ZEVASKYN incorporates the functional type VII collagen-producing COL7A1 gene into a patient’s own skin cells, ex vivo, using a replication-incompetent retroviral vector to produce functional type VII collagen in treated wounds. ZEVASKYN has demonstrated clinically meaningful wound healing and pain reduction with a single surgical application. For more information, visit www.ZEVASKYN.com.
Indication
ZEVASKYN® (prademagene zamikeracel) is an autologous cell sheet-based gene therapy indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).
Important Safety Information
- Serious allergic reactions to ZEVASKYN can occur. Patients should get medical help right away if they experience symptoms like itching, swelling, hives, difficulty breathing, runny nose, watery eyes, or nausea. In rare cases, a severe reaction called anaphylaxis may happen.
- There is a potential risk that treatment with ZEVASKYN may contribute to the development of cancer because of how the therapy works. Patients should be monitored for the rest of their lives to check for any signs of cancer.
- ZEVASKYN is made using human and animal materials. Although these materials are tested before use, the risk of passing on infections cannot be eliminated.
- The most common side effects are pain from the procedure and itching.
This is not a complete list of side effects. Patients should call their care team for medical advice about side effects. Side effects may be reported to Abeona at 1-844-888-2236 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
See full Prescribing Information.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.
ZEVASKYN®, Abeona Assist®, Abeona Therapeutics®, and their related logos are trademarks of Abeona Therapeutics Inc.
Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, our ability to successfully commercialize and market ZEVASKYN, including manufacturing sufficient batches of ZEVASKYN to meet demand; the therapeutic potential of ZEVASKYN; whether the unmet need and market opportunity for ZEVASKYN are consistent with the Company’s expectations; continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with and inspections by the FDA or other regulatory agencies, including those relating to preclinical programs and to the cGMP manufacturing of ZEVASKYN; the ability to achieve or obtain necessary regulatory approvals for our pre-clinical programs; the impact of any changes in the financial markets and global economic conditions, including those resulting from changes to U.S. trade policy, such as current or future tariffs; risks associated with data analysis and reporting; and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise these forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.
Contacts:
Investor and Media
Greg Gin
VP, Investor Relations and Corporate Communications
Abeona Therapeutics
ir@abeonatherapeutics.com
Investor
Lee M. Stern
Meru Advisors
lstern@meruadvisors.com
